Phase 1 Triple Negative Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
BreastCancerMetastatic+2 more
University of Southern California65 enrolled3 locationsNCT04333706
Recruiting
Phase 1
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.70 enrolled8 locationsNCT02926690
Recruiting
Phase 1
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Phase 1Phase 2
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting
Phase 1Phase 2
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Breast CancerBreast Cancer MetastaticBreast Carcinoma+1 more
Essen Biotech85 enrolled1 locationNCT06532812